{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:23:03Z","timestamp":1791397383289,"version":"4.3.3"},"reference-count":36,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T00:00:00Z","timestamp":1343174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2013,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Patients with peripheral T\u2010cell lymphomas (PTCLs) have inferior progression\u2010free survival (PFS) and overall survival (OS) compared with patients who have aggressive B\u2010cell non\u2010Hodgkin lymphoma. Because PTCLs over express multidrug resistance gene 1\/P\u2010glycoprotein (MDR\u20101\/P\u2010gp), we devised platinum, etoposide, gemcitabine, and methylprednisolone (PEGS) with agents that are not substrates of the efflux pump. Gemcitabine was included because of its excellent single\u2010agent activity in PTCL.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Patients who had PTCL with stage II bulky disease, stage III or IV disease with extra\u2010nodal, nodal, and transformed cutaneous presentations were eligible. Patients received intravenous cisplatin 25 mg\/m<jats:sup>2<\/jats:sup> on days 1 through 4, etoposide 40 mg\/m<jats:sup>2<\/jats:sup> on days 1 through 4, gemcitabine 1000 mg\/m<jats:sup>2<\/jats:sup> on day 1, and methylprednisolone 250 mg on days 1 through 4 of a 21\u2010day cycle for 6 cycles.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>In total, 34 patients were enrolled, 33 were eligible, and 79% were newly diagnosed. Histologic types were PTCL not otherwise specified (n = 15), anaplastic lymphoma kinase (ALK)\u2010negative anaplastic large cell lymphoma (n = 4), angioimmunoblastic T\u2010cell lymphoma (n = 6), or other T\u2010cell non\u2010Hodgkin lymphomas (n = 8). Adverse events included 1 grade 5 infection with grade 3 or 4 neutropenia and 9 grade 4 hematologic toxicities. The overall response rate was 39% (47% in PTCL not otherwise specified, 33% in angioimmunoblastic T\u2010cell lymphoma, 25% in ALK\u2010negative and 38% in other T\u2010cell non\u2010Hodgkin lymphomas). The PFS rate at 2 years was 12% (95% confidence interval, 0.1%\u201031%), and the median PFS was 7 months. The OS rate at 2 years was 30% (95% confidence interval, 8%\u201054%), and the median OS was 17 months. Immunohistochemical analysis of P\u2010gp expression revealed strong positivity in a subset of lymphoma cells (n = 6) and tumor endothelium (n = 25).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Overall, PEGS was well tolerated, but OS was not considered promising given the design\u2010specified targets. These results may serve as a benchmark for future comparisons for non\u2010CHOP regimens. Cancer 2013. \u00a9 2012 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.27733","type":"journal-article","created":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T10:09:18Z","timestamp":1343210958000},"page":"371-379","source":"Crossref","is-referenced-by-count":74,"title":["Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T\u2010cell non\u2010Hodgkin lymphoma"],"prefix":"10.1002","volume":"119","author":[{"given":"Daruka","family":"Mahadevan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Spier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel O.","family":"Persky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fay","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard I.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,25]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/asheducation-2008.1.280","article-title":"Prognosis and primary therapy in peripheral T\u2010cell lymphomas","author":"Savage KJ","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"e_1_2_8_3_2","volume-title":"WHO classification of Tumors of Hematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7171"},{"key":"e_1_2_8_5_2","first-page":"3152","article-title":"ALK\u2212 anaplastic large\u2010cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T\u2010cell lymphoma, not otherwise specified: report from the International Peripheral T\u2010Cell Lymphoma Project","volume":"103","author":"Savage KJ","year":"2008","journal-title":"Blood."},{"key":"e_1_2_8_6_2","first-page":"76","article-title":"Prognostic significance of T\u2010cell phenotype in aggressive non\u2010Hodgkin's lymphomas","volume":"92","author":"Gisselbrecht C","year":"1998","journal-title":"Blood."},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-231548"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.02.008"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.137"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.945"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2490"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2603"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3656-4"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03067.x"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_8_18_2","first-page":"623924","article-title":"A systematic review and meta\u2010analysis of front\u2010line anthracycline\u2010based chemotherapy regimens for peripheral T\u2010cell lymphoma [serial online]","author":"Abouyabis AN","year":"2011","journal-title":"ISRN Hematol"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2005.n.030"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2095"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1169"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn022"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08329.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.4870"},{"key":"e_1_2_8_25_2","first-page":"118","article-title":"High\u2010dose chemotherapy and autologous stem cell transplantation in previously untreated peripheral T\u2010cell lymphoma\u2014final analysis of a large prospective multicenter study (NLG\u2010T\u201001) [abstract]","author":"d'Amore F","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0136-y"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-074641"},{"issue":"4","key":"e_1_2_8_28_2","article-title":"Preliminary results from an open\u2010label, multicenter, phase II study of bendamustine in relapsed or refractory T\u2010cell lymphoma from the French GOELAMS group: the Bently Trial [abstract]","volume":"22","author":"Damaj G","year":"2011","journal-title":"Ann Oncol."},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9523-2"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10737"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3389"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.9.2451.2451"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2010.03.003"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1078\/0940-2993-00287"},{"key":"e_1_2_8_37_2","first-page":"3387","article-title":"Hypoxia\u2010inducible factor\u20101\u2010dependent regulation of the multidrug resistance (MDR1) gene","volume":"62","author":"Comerford KM","year":"2002","journal-title":"Cancer Res."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.27733","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.27733","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.27733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:53:25Z","timestamp":1760270005000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.27733"}},"subtitle":["Southwest Oncology Group Study S0350"],"short-title":[],"issued":{"date-parts":[[2012,7,25]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,1,15]]}},"alternative-id":["10.1002\/cncr.27733"],"URL":"https:\/\/doi.org\/10.1002\/cncr.27733","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,25]]}}}